Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Examining a Preclinical Alzheimer’s Cognitive Composite for Telehealth Administration, the tPACC, for Reliability between In-Person and Remote Cognitive Testing
Aging, Dementia, and Behavioral Neurology
P6 - Poster Session 6 (5:30 PM-6:30 PM)
7-002

The clinical trial landscape in Alzheimer’s disease (AD) and related dementias is focused on targeting individuals in preclinical stages. The preclinical Alzheimer’s cognitive composite (PACC) was developed for in-person administration to capture subtle cognitive decline in amyloid positive individuals compared to amyloid negative. It is desirable to have a transportable, composite measurement sensitive to detecting cognitive changes across cognitively normal (NC) and impaired (MCI and dementia) participants.

To evaluate the concordance of tPACC scores from in-person and remote testing.

We examined in-person cognitive data from 662 adults (70.2±8.1y) from the Wake Forest AD Research Center’s Clinical Core, who received clinical evaluation, cognitive testing, and adjudication. The PACC in-person only was calculated using RAVLT Delayed Recall, Digit Symbol Coding (DSC), semantic fluency, Craft Story Delayed Verbatim, and MMSE total scores using baseline NC participants as a reference. The tPACC used measurements that were available at both in-person and remote visits with modifications from the in-person PACC; Montreal Cognitive Assessment (MoCA) was used in place of MMSE, and DSC was not included. A subset analysis with PACC in-person and tPACC remote from a pilot study examined reliability between in-person and remote testing. We performed correlation analysis and generated Bland-Altman plots.
Of the 662 adults studied, 434 (66%) were female, 522 (79%) were White, 206 (34%) were APOE4 carriers, and mean education was 15.9±4.1 years. At baseline, there is a significant positive relationship between in-person tPACC and PACC (Overall group; r2=0.94, p=<0.0001, n=640). Although there is a good agreement in both subgroups (Impaired: r2=0.86, p=<0.0001, n=301 and NC: r2=0.90, p=<0.0001, n=328), tPACC overestimates cognitive performance compared to PACC for those with lower scores. We also found good agreement between in-person PACC and remote tPACC (r2=0.83, p=<0.0001, n=38).
There is generally good agreement between tPACC and PACC for NC and impaired individuals.
Authors/Disclosures
Tugce Duran
PRESENTER
Miss Duran has nothing to disclose.
No disclosure on file
Samuel N. Lockhart, PhD (Wake Forest School of Medicine) The institution of Dr. Lockhart has received research support from NIH.
No disclosure on file
Mark Espeland, PhD The institution of Dr. Espeland has received research support from Alzheimer's Association. The institution of Dr. Espeland has received research support from National Institutes of Health. Dr. Espeland has received personal compensation in the range of $500-$4,999 for serving as a Consultant with National Institutes of Health.
Benjamin J. Williams, MD, PhD, FAAN Dr. Williams has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
James R. Bateman III, MD (Atrium Health Wake Forest Baptist) Dr. Bateman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. The institution of Dr. Bateman has received research support from NIA. The institution of Dr. Bateman has received research support from Dementia Alliance of North Carolina. The institution of Dr. Bateman has received research support from Alzheimer's Association. The institution of Dr. Bateman has received research support from Alzheimer's Drug Discovery Foundation. Dr. Bateman has a non-compensated relationship as a Committee Member with UCNS that is relevant to AAN interests or activities.